NewCelX is advancing NCEL-101 using a proprietary differentiation and enrichment platform designed to produce highly purified, functional insulin-producing islet cells.
Public source
Publisher name
Public post
Not every insulin-producing cell is the same. A new review in Nature Reviews #Endocrinology examines how closely stem cell-derived beta cells resemble mature human beta…
Company
NewCelX
Biotechnology company advancing transformative therapies for neurodegenerative and metabolic diseases
- Industry
- Biotechnology Research
- Location
- Kloten, CH
- Company size
- 11–50 employees
About NewCelX
NewCelX Ltd. (Nasdaq: NCEL) is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company’s integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. NewCelX is headquartered in Zurich, Switzerland, with research and development operations in Ness Ziona, Israel.
See moreLatest activity
Latest activity from NewCelX
3 signals
Research & Knowledge
NewCelX and NCEL-101 preclinical stem cell-derived islet cell therapy was highlighted by the Breakthrough T1D Center of Excellence at UMass Chan Medical School as a critical requirement for type 1 diabetes cell therapy.
Research & Knowledge
NewCelX is developing NCEL-101, an enriched stem cell-derived islet cell therapy designed to restore functional insulin production through scalable, off-the-shelf cell replacement.
Discover more
Similar signals
Similar public activity from other companies.
Products & Services
RoosterBio Inc.
RoosterBio Inc. developed AgentV™-DSP, a novel reagent that increases exosome recovery ten-fold to 40-70% while maintaining critical quality attributes (CQAs) for scalable GMP-compatible MSC-derived extracellular vesicles production.
Products & Services
Ncardia
Ncardia launched the Ncyte IO Safety Panel, a single workflow that combines human iPSC-derived neurons, cardiomyocytes, endothelial cells, melanocytes, hepatocytes, intestinal epithelial cells, and alveolar epithelial cells to compare functional toxicity across multiple tissues.
Products & Services
Shinobi Therapeutics
Shinobi Therapeutics designed its lead program NJA-201 from the ground up as an engineered, off-the-shelf, iPSC-derived cell therapy.
Products & Services
REPROCELL
REPROCELL developed StemRNA™ Clinical iPSC Seed Clones with major-market regulatory expectations in mind.
Products & Services
Capricor Therapeutics, Inc.